CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 91 enrolled
Drug / intervention
Triamcinolone acetonide nasal spray +1 moredrug
Likely dose
Triamcinolone acetonide nasal spray: ages 12+: 220 micrograms daily (2 sprays × 55 micrograms in each nostril once daily); ages <12: 110 micrograms daily (1 spray × 55 micrograms in each nostril once daily)AI-extracted
Key inclusion· 2
  • Male or female, age 0-18 years
  • Serous otitis media and/or negative middle ear pressure documented by otoscopic examination and tympanometry
Key exclusion· 15
  • Unwilling to discontinue breast feeding, when applicable
  • Active upper respiratory infection
  • Nasopharyngeal mass
  • Chronic infectious otitis media

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00279916
NCT00279916Phase 3Completed

Short Term Relief of Eustachian Tube Dysfunction and Serous Otitis Media Using Intranasal Steroid Sprays: a Randomized Placebo-controlled Study

Mayo Clinic·interventional·Posted Jan 20, 2006·Updated May 30, 2017

In Brief

A Phase 3 clinical trial evaluating Triamcinolone acetonide nasal spray and Placebo nasal spray for Otitis Media, Serous and 4 related conditions. Completed, enrolled 91 participants across 1 site.

Detailed Summary

We hypothesize that intranasal steroid application will have a beneficial therapeutic effect in adults with regard to resolution of serous otitis media and/or negative middle ear pressure, as compared to placebo. We further hypothesize that the rate of spontaneous short-term resolution of otitis media wit effusion in adults treated with placebo will be relatively low (minority of patients).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 20, 2006
Enrollment StartSep 1, 2005
Primary CompletionFeb 1, 2009
Study CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 20.4 years ago

Interventions

Triamcinolone acetonide nasal spraydrug

Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms). Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms).

Placebo nasal spraydrug

Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily. Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily.